MedTrace Logo

Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG

NCT02947867 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 333

Last updated 2016-10-31

No results posted yet for this study

Summary

A prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG Study

Conditions

  • Ischaemic Central Retinal Vein Occlusion
  • Neovascular Glaucoma

Interventions

DRUG

aganirsen

aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)

Sponsors & Collaborators

  • Johannes Gutenberg University Mainz

    collaborator OTHER

  • University Hospital of Cologne

    collaborator OTHER

  • Moorfields Eye Hospital NHS Foundation Trust

    collaborator OTHER

  • Gene Signal SAS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-06-30
Completion
2019-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02947867 on ClinicalTrials.gov